Mostrar o rexistro simple do ítem

dc.contributor.authorCasal, Bruno
dc.contributor.authorRodríguez-Míguez, Eva
dc.contributor.authorRivera, Berta
dc.date.accessioned2024-01-12T16:27:33Z
dc.date.issued2020
dc.identifier.citationCasal, B., Rodríguez-Míguez, E. & Rivera, B. Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments. Eur J Health Econ 21, 1039–1048 (2020). https://doi.org/10.1007/s10198-020-01196-7es_ES
dc.identifier.issn1618-7601
dc.identifier.issn1618-7598
dc.identifier.urihttp://hdl.handle.net/2183/34886
dc.description.abstract[Abstract] Objective: Drug and/or alcohol dependence (DAD) generates substantial costs to society. One of the main consequences of DAD is its negative impact on health-related quality of life (HRQoL). The main objective of this study is to analyse the impact of using EQ-5D-5L, SF-6DSG (SF-6D using standard-gamble as the preference-eliciting method) and SF-6DPG (SF-6D using a paired-gamble method), to estimate the HRQoL burden, attributable to DAD, within the cost-of-illness framework. Methods: A convenience sample of 109 patients with a diagnosis of substance use disorder was recruited. SF-6D and EQ-5D-5L were administered and then the utility scores were computed. The impact of employing different instruments to estimate the HRQoL burden was assessed by comparing the utility scores of patients and general population after controlling for sex and age through regression analysis. The analysis was reproduced for two subgroups of severity. Results: All instruments detect that DAD significantly affects the HRQoL. However, the estimated impact changes, according to the instrument used, whose pattern varies by severity group. Nonetheless, regardless of severity, SF-6DPG always estimates a higher or equal DAD burden than the other instruments considered. These results are compatible with the presence of the floor effect in SF-6DSG, the ceiling effect in EQ-ED-5L, and a smaller presence of both biases in SF-6DPG. Conclusions: The SF-6DPG instrument emerges as a good candidate to avoid under-estimating intangible costs within the cost-of-illness framework. However, further research is needed to assess the validity of our results in the context of other health problems.es_ES
dc.description.sponsorshipFunding: Ministerio de Sanidad, Servicios Sociales e Igualdad (2013I027), Ministerio de Ciencia, Innovación y Universidades (RTI2018-099403-B-100)es_ES
dc.description.sponsorshipMinisterio de Sanidad, Servicios Sociales e Igualdad; 2013I027es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relationinfo: eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-099403-B-I00/ES/ESTUDIOS EMPIRICOS DE ECONOMIA INDUSTRIAL Y ECONOMIA DE LA SALUD. APLICACIONES CON DATOS MICROECONOMICOSes_ES
dc.relation.urihttps://doi.org/10.1007/s10198-020-01196-7es_ES
dc.rights© Springeres_ES
dc.subjectEQ-5D-5Les_ES
dc.subjectSF-6Des_ES
dc.subjectPaired-gamblees_ES
dc.subjectSubstance dependencees_ES
dc.subjectIntangible costes_ES
dc.titleMeasuring Intangible Cost-Of-Morbidity Due to Substance Dependence: Implications of Using Alternative Preference-Based Instrumentses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate9999-99-99es_ES
dc.date.embargoLift10007-06-07
UDC.journalTitleThe European Journal of Health Economicses_ES
UDC.volume21es_ES
UDC.startPage1039es_ES
UDC.endPage1048es_ES
dc.identifier.doihttps://doi.org/10.1007/s10198-020-01196-7


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem